StemCell Therapy

Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer. Intravesical BCG therapy is widely-used for bladder cancer. However, tumor recurrence and progression are very common. Stratification based on germline polymorphisms may contribute to circumvent this clinical challenge. Autophagy pathway plays an important role in the nonspecific protective effects of BCG. Patients that carry C allele of rs3759601 in autophagy gene ATG2B showed increased risk of recurrence and progression in European population. We thus sought to analyze rs3759601 and its relevance in BCG response in Asian NMIBC patients.

Functional impact of rs3759601 ATG2B (p.Gln1383Glu) was analyzed by bioinformatics programs including NCBI Conserved Domain Search, Clustal Omega, Polyphen and SIFT. NMIBC patients who received intravesical BCG at multiple hospitals in Singapore from 1995 to 2016 were included. These patients were genotyped for rs3759601 using high resolution melt analysis. The rs3759601 polymorphism was studied in correlation with the bladder cancer recurrence rate and disease progression rate in our cohort. Statistical analysis was conducted using Kaplan-Meier plots and the Chi-squared analysis.

In total, 307 individules were included in the study including 161 NMIBC patients and 146 healthy controls, predominately Chinese. The rs3759601 genotype distributions in our NMIBC patients were (GG 72.1%; GC 27.9%; CC 0%), which were distinct from the Dutch report (GG 32.8%; GC 47.4% and CC 19.8%, Buffen K et al, 2014). Consistently, the C allele frequencies of rs3759601 are 0.171 in our controls and 0.177 in East Asians from 1,000 Genome, but 0.406 in Europeans from 1,000 Genome. In silico analysis suggested rs3759601 ATG2B (p.Gln1383Glu) alteration is unlikely to be functionally deleterious. Statistical analysis revealed no significant association between ATG2B rs3759601 C allele and risk of bladder cancer recurrence (P= 0.353, GC vs. GG: hazard ratio [HR]= 1.324), or cancer progression (P= 0.454, GC vs. GG: HR=0.658).

In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients.

Urologic oncology. 2020 Nov 26 [Epub ahead of print]

Zhijiang Zang, Yew Koon Lim, Yiong Huak Chan, Lata Raman, Kesavan Esuvaranathan, Edmund Chiong, Ratha Mahendran

Department of Urology, National University Hospital, National University Health System, Singapore. Electronic address: ., Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33250346

Read the original:
Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Ba... - UroToday

The Scientist's annual award recognizes exciting biomedical technologies that have the potential to generate the biggest impact on scientific research. Seven Bridges GRAF was selected by The Scientist's independent panel of expert judges for its potential to improve methods for analyzing next-generation sequencing data, helping researchers overcome the inherent flaws in the human genome linear reference sequence, and improving understandings of genetic diversity in understudied populations such as people of African, Asian, Hispanic and Middle Eastern descent.

"Seven Bridges is the first to offer this type of graph-based bioinformatics solution," said William Moss, CEO of Seven Bridges. "This recognition underscores the greater importance Seven Bridges GRAFTMbrings to the research community and its value in helping scientists develop new understandings of global population diversity. We hope that this research ultimately improves precision medicine across global populations."

The company's comprehensive graph-based bioinformatics solution is designed to greatly improve the analysis of non-European ethnicities; support large, more diverse population studies; enable research on underrepresented populations; and aid in the development of personalized references for more precise analysis. Seven Bridges GRAF enables:

"The COVID-19 pandemic birthed a shared scientific purpose and accelerated innovation in 2020," said The Scientist Editor-in-Chief Bob Grant. "The winners of this year's competition embody the spirit of togetherness and ingenuity marshaled by the research community in the face of this unprecedented challenge."

In addition to the honor from The Scientist, this year, Seven Bridges GRAF was selected as the top performer in the precisionFDA Truth Challenge for the major histocompatibility complex (MHC) region. The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region.

"The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region," said Dr. H. Serhat Tetikol, the GRAF Product Director at Seven Bridges. "From a computational perspective, the complexity of such genomic loci is only exacerbated when one takes into account the variation between different ancestries. This is where the current linear human genome reference clearly falls short, and where our GRAF technology can provide significant utility over traditional methods."

For more information about Seven Bridges GRAF, visit http://www.sevenbridges.com/graf/.

About Seven BridgesSeven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated data sets, and expert on-demand professional services. This holistic approach to bioinformatics is enabling researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and even turn a failing clinical trial around while also reducing computational workflow times and data storage costs. To learn more, visitsevenbridges.comor follow us onLinkedInandTwitter.

Contact: Eric Schubert +1 415 692 6799 [emailprotected]

SOURCE Seven Bridges

Home

Read the rest here:
Seven Bridges GRAF Named #3 on The Scientist's Top 10 Innovations List for 2020 - PRNewswire

Hologics Jennifer Meade, division president of breast and skeletal care, discusses the focus for breast imaging in the near future and some latest technologies.

Hologic received 510(k) clearance from the U.S. Food & Drug Administration for its Genius AI Detection software this week during the Radiology Society of North America (RSNA) annual meeting. This move is one more development that is feeding growing trends in breast imaging, said Jennifer Meade, division president of breast and skeletal care for womens imaging vendor Hologic.

Meade spoke with Diagnostic Imaging not only about some of Hologics more recent product offerings, but she also discussed feedback from the radiology community and some growing trends in breast imaging. In the coming years, she said, the industry can expect to see a greater focus on improved patient outcomes, workflow efficiency, and patient experience. In addition, she said developments and investments will continue around artificial intelligence, as well as personalized medicine.

With this latest FDA clearance, the Genius AI Detection software is set to follow that path, according to company information. It is designed to optimize workflow in four specific ways by providing a case score that reflects confidence of malignancy, categorizing cases based on the number of lesions present, flagging the most concerning cases in less than a minute, and providing an estimate of how much time a radiologist can expect the image review to take.

For more RSNA coverage, click here.

Read more:
Trends in Breast Imaging Care: Improving Outcomes, Efficiency, and Experience - Diagnostic Imaging

DataIntelo, a prominent market research firm, has published a detailed report on Global Personalized Medicines Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Personalized Medicines market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. DataIntelo has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://dataintelo.com/checkout/?reportId=98645

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Personalized Medicines market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=98645

Market Segmentation

Some of the major companies that are covered in the report.

3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIllumina

Note: Additional companies

Based on the type, the market is segmented into

PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Based on the application, the market is segregated into

Hospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

DataIntelo provides yearly updates on the Personalized Medicines market that assist the clients to stay ahead in the competitive space.

Why one should buy this Personalized Medicines Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

DataIntelo bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Personalized Medicines Market Overview

Personalized Medicines Supply Chain Analysis

Personalized Medicines Pricing Analysis

Global Personalized Medicines Market Analysis and Forecast by Type

Global Personalized Medicines Market Analysis and Forecast by Application

Global Personalized Medicines Market Analysis and Forecast by Sales Channel

Global Personalized Medicines Market Analysis and Forecast by Region

North America Personalized Medicines Market Analysis and Forecast

Latin America Personalized Medicines Market Analysis and Forecast

Europe Personalized Medicines Market Analysis and Forecast

Asia Pacific Personalized Medicines Market Analysis and Forecast

Asia Pacific Personalized Medicines Market Size and Volume Forecast by Application

Middle East & Africa Personalized Medicines Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=98645

About the Company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Continued here:
Personalized Medicines Market 2020 |Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026| Latest Research...

CHICAGO, Nov. 26, 2020 /PRNewswire/ -- BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting.

Study will expand access to antibody testing outside of laboratory settings

Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available.

At present, most antibody tests on the market require samples to be sent to a lab for analysis. The extra cost and time associated has constrained population wide studies of SARS-CoV-2 antibodies.

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December.

About BASE10 Genetics, Inc.BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

For more information about BASE10 Genetics and its solutions, contact media@base10genetics.com.

About DNA Link, Inc.DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry.

For more information about DNA Link and its solutions, contact ikjun.choi@dnalink.com

View original content:http://www.prnewswire.com/news-releases/base10-and-dna-link-partners-on-research-to-support-authorization-of-antibody-test-at-the-point-of-care-301181072.html

SOURCE BASE10 Genetics, Inc.

Read the rest here:
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care - BioSpace

The Personalized Medicines Market grew in 2019, as compared to 2018, according to our report, Personalized Medicines Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Personalized Medicines Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Personalized Medicines Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-personalized-medicines-market-2020-market-size-share-growth-trends-forecast-2025/

The Personalized Medicines Market is analysed based on product types, major applications and key players

Key product type:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Key applications:Hospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Key players or companies covered are:3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIllumina

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-personalized-medicines-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Personalized Medicines Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Personalized Medicines Market?4. What is the likely market forecast & how will be Personalized Medicines Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Personalized Medicines Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Continued here:
Personalized Medicines Market Segmentation by Application, Market landscape, Market size and forecast by 2026 - The Market Feed

Latest added DNA Sequencing Market research study by MarketDigits offers detailed product outlook and elaborates market review till 2026. The market Study is segmented by key regions that is accelerating the marketization. At present, the market is sharping its presence and some of the key players in the study are GE Healthcare Life Sciences, Johnson & Johnson, Commonwealth Biotechnologies, ZS Genetics, Agilent Technologies, Siemens AG. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

This report studies the DNA Sequencing Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the DNA Sequencing Market by companies, region, type and end-use industry.

Request for Free Sample Copy of This Report (with COVID-19 Impact ) @ https://marketdigits.com/dna-sequencing-market/sample

Scroll down 100s of data Tables, charts and graphs spread through Pages and in-depth Table of Content on DNA Sequencing Market By Product Type (Instruments, Consumables, and Others), Platform (Sanger, Next Generation Sequencing, qPCR, and Others), Application (Diagnostics, Personalized Medicine, and Others), End User (Hospitals & Healthcare Organizations, Academics & Research Institutions, Pharmaceutical & Biotechnology Companies, and Others) and Geography Global Forecast To 2026. Early buyers will get 10% customization on study.

To Avail deep insights of DNA Sequencing Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2018-2020), Segment Revenue Market Share (%) by Players (2018-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Unlock new opportunities in DNA Sequencing Market; the latest release from MarketDigits highlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider to gain better insights.

Grab Complete Details with TOC For Free @ https://marketdigits.com/dna-sequencing-market/toc

Global DNA Sequencing Market: Synopsis

The global DNA sequencing market is projected to achieve an impressive growth rate on the back of its extensive usage in a number of applications and ease of adoption with the emergence of innovative technologies in the field. A DNA sequencing Android app named GelApp 2.0 has been recently introduced with a 56.0% greater band detection accuracy for proteins and 36.0% for DNA than its original version. The interesting, rather most innovative, part of the apps development procedure was the implementation of Monte Carlo Tree Search, a gaming algorithm, for cutting-edge image processing.

With a healthy CAGR of 17.5%, the worldwide DNA sequencing market is foretold to expand substantially from an estimated US$6.6 billion in 2016.

The segmentation followed in this global DNA sequencing report touches four important parameters, including technology. With the help of such critical market segmentation, the analysts have provided a comprehensive study of the global market and significant segments that are envisaged to make a statement in the near future. An illustrative portion on SWOT analysis of the chief segments of the DNA sequencing sector, including characteristic graphics, helps to easily analyze the future outlook of the market.

The report on the international DNA sequencing market takes into account the industry growth drivers, challenges for market players, and current trends impacting the industry. With such conclusive data and accurate statistics, report buyers can devise result-oriented strategies to secure a competitive place in the global market. An in-depth evaluation of the key factors of the market illustrated in the report is a crucial stepping stone to make important business decisions.

Global DNA Sequencing Market : Trends and Opportunities

New market players are envisioned to get attracted to the global DNA sequencing market as technological innovations keep taking precedence. Besides this, established players can expect to leverage new opportunities in the market with sophisticated technologies such as chain terminator DNA sequencing and next generation DNA sequencing. Vendors can also find lucrative opportunities in the clinical field as DNA sequencing is highly demanded in numerous clinical applications. Next generation DNA sequencing, particularly, is receiving high attention with the providence of novel platforms from the ongoing quantum leaps in microfluidics, bioinformatics, nanotechnology, and imaging. Such breakthroughs are also predicted to revolutionize a number of life science fields, thus providing an easy path of growth for the global market.

The services segment of the international DNA sequencing market had secured a colossal share in 2016 while instruments and consumables was one of the most rapidly growing segments in the same year.

Global DNA Sequencing Market: Geography

Considering the most critical geographical regions as a base, the analysts have offered an all-encompassing interpretation of the global DNA sequencing market. North America, Europe, Asia Pacific, and Rest of the World are the major geographies studied in the report. North America could hold a momentous share in the global market while Asia Pacific is anticipated to take advantage of the demand for personalized medicine and higher awareness.

Global DNA Sequencing Market: Company Profiling

Among other prominent players in the global DNA sequencing market, Microchip Biotechnologies, Beckman Coulter (Fullerton, CA), Abbott Laboratories, GE Healthcare Life Sciences, Johnson & Johnson, Commonwealth Biotechnologies, ZS Genetics, Agilent Technologies, Siemens AG, Pacific Biosciences, Myriad Genetics, Bayer Corporation, Integrated DNA Technologies, 454 Life Sciences, Hamilton Thorne Biosciences, and LI-COR Biosciences (Lincoln, NE) are expected to make their presence known.

Market segmentation based on type:

Market segmentation based on technology:

This study by MarketDigits is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers or customers journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Actionable Results

The findings presented in this study by MarketDigits are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

3. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at MarketDigits helps you break down the complex scenario and bring resiliency in uncertain times.

The DNA Sequencing market research report makes an organization armed with data and information generated by sound research methods. This market analysis helps to get up to date about various segments that are relied upon to observe the rapid business development amid the estimate forecast frame. This market research report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost & gross margin. DNA Sequencing market report plays very essential role when it is about achieving an incredible growth in the business.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

DNA Sequencing Market Reports Table of Contents

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

4.1. Introduction

4.2. Overview

4.3. Market Dynamics

4.4. Porters Five Force Analysis

5.1. Technological Advancements

5.2. Pricing Analysis

5.3. Recent Developments

Any Questions? Inquire Here Before Buying @ https://marketdigits.com/dna-sequencing-market/analyst

About Market Digits :

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

Contact Us :

Market Digits

Phone : +91-9822485644

Email : sales@marketdigits.com

Read the original post:
DNA Sequencing Market : Overview Report by 2020, Covid-19 Analysis, Future Plans and Industry Growth with High CAGR by Forecast 2026 - The Courier

Precision medicine is in its nascent stages, but the field is rapidly growing, adding another catalyst to an already lengthy list for the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG).

One of the driving forces behind ARKGs enviable long-term track records is its the managers ability to identify disruptive forces in the healthcare and genomics arenas. The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Put simply, precision medicine is the application of technology to biology, and its one of the most innovative ideas in the healthcare arena.

Many precision-medicine techniques offer the potential for disease prevention, driving the potential for cost savings and patient-outcome improvements, said Dr. Charles Kennedy, CEO and managing partner at Blue Ox Healthcare Partners, in an interview with Barrons. One example is pre-term birth, which represents more than $32 billion in health-care spending in the U.S.in part due to its occurrence in one in every 10 pregnancies, and as many as one in every five pregnancies in the African American population. While many interventions are used to reduce the morbidity and mortality of pre-term birth, a fundamental problem that exists is the inability to identify women at risk for a pre-term delivery.

The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Everything about health care is changing and will continue to do so. Where you receive your care is evolving based on convenience and integration with daily life, said Kennedy. For example, weve seen more medical retail locations in shopping environments. Additionally, technology that remotely monitors patients who might otherwise need to be in a care setting is changing.

Gene sequencing and precision medicine are viewed as vital avenues for success in developing COVID-19 treatments. Bolstering the long-term case for genetic sequencing is the fields ability to help healthcare professionals more accurately diagnose ailments, delivering a higher level of personalized patient care.

While precision medicine might have only indirect impacts on issues such as access and costs, it transcends race by digitizing your biology and characterizing what makes you uniquely you, notes Kennedy in the Barrons interview. Simply put, you have the biology to take advantage of a drug or other treatment, or you dont. As such, more quantitative and discrete measures of disease and intervention opportunities make care more objective, less subjective, and more precisely aligned with the greatest likelihood of the best patient outcome, no matter who you are or where you come from.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Read more here:
How Precision Medicine Will Revolutionize Healthcare - ETF Trends

Study will expand access to antibody testing outside of laboratory settings

At present,mostantibody tests on the market require samples to be sent to a lab for analysis.The extra cost and time associated hasconstrainedpopulation wide studies ofSARS-CoV-2antibodies.

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December.

About BASE10 Genetics, Inc.BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

For more information about BASE10 Genetics and its solutions, contact [emailprotected].

About DNA Link, Inc.DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry.

For more information about DNA Link and its solutions, contact[emailprotected]

SOURCE BASE10 Genetics, Inc.

https://www.base10genetics.com/

Read this article:
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care - PRNewswire

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD., effective December 1, 2020. Mr. Stover, who will step down from the Interpace Board of Directors once Dr. Burnell joins the company and is appointed to the Board, will serve as an advisor to the company through the middle of 2021 in order to support the transition.

Dr. Burnell joins Interpace with significant leadership experience with numerous healthcare companies, including a number of specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories and Eurofins Scientific, Inc. in addition to senior leadership roles with other companies such as Elite One Source, Nebraska Heart Institute, and most recently with the Pioneer Heart Institute.

Robert Gorman, Chairman of the Board for Interpace, commented, On behalf of the Board, I thank Jack for his leadership and service to the company. He has led the company through both difficult and transformational times, and has helped to position the company for strong growth in the future.

After careful reflection, I have decided that now is the right time to retire and help the company through a thoughtful succession process, said Mr. Stover. It has been a privilege to lead Interpace over the past four years, and I am proud to have been a part of the phenomenal team of dedicated professionals at Interpace which has worked tirelessly to improve the care of patients suspected of having cancer.

Dr. Burnell added, I am thrilled to join the Interpace team at such an exciting and pivotal point in the companys history. Interpace has a strong reputation as a patient-centric organization, and over the years has developed an impressive product and service offering that is particularly critical given the challenging demands of cancer care. I look forward to working with the entire leadership team to continue the companys growth as a leading provider of specialty oncology-focused diagnostic services and customized pharma services.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:Investor RelationsEdison GroupJoseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com / mpaul@edisongroup.com

Read more:
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as...

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms" report has been added to ResearchAndMarkets.com's offering.

The research provides technological insights across inflammation, infectious diseases, and microbiomics.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness from:

For more information about this report visit https://www.researchandmarkets.com/r/tkufmb

Continued here:
2020 Report: Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms - ResearchAndMarkets.com - Business Wire

Precision-Medicine-MarketOverview of Precision Medicine Market 2020-2026:

Global Precision Medicine Market 2020 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. Research reports analyses the major opportunities, CAGR, yearly growth rates to help the readers to understand the qualitative and quantitative aspects of theGlobal Precision MedicineMarket. The competition landscape, company overview, financials, recent developments and long-term investments related to theGlobal Precision Medicine Marketare mentioned in this report.

The key segments covered in this report are geographical segments, end-use/application segments, and competitor segments. The local segment, regional supply, application, and wise demand, major players, prices are also available by 2026. Global Precision Medicine Market are mentioned in the competition landscape, company overview, financials, recent developments and long-term investments.

Get PDF Sample Copy of the Report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/217480

Top Key players profiled in the Precision Medicine market report include:Johnson & Johnson, IBM, GE Healthcare, Illumina, Roche, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Novartis, Abbott Laboratories, Almac Group, Intel Corporation, Biomrieux Sa, Cepheid, Qiagen, Randox Laboratories, Healthcore and More

Based on the type of product, the global Precision Medicine market segmented into: Diagnostics TherapiesBased on the end-use, the global Precision Medicine market classified into: Oncology Neurosciences Immunology Respiratory Others

global Precision Medicine market report also highlights key insights on the factors that drive the growth of the market as well as key challenges that are required to Precision Medicine market growth in the projection period. Here provide the perspectives for the impact of COVID-19 from the long and short term. Precision Medicine market contain the influence of the crisis on the industry chain, especially for marketing channels. Update the industry economic revitalization plan of the country-wise government.

To Understand the influence of COVID-19 on the Set Screw Market with our analysts monitoring the situation across the globe. Get here sample analysis

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026Regions Covered in the Global Precision Medicine Market:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key questions answered in this report:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/217480

Key point summary of the Global Precision Medicine Market report:

Detailed TOC of Precision Medicine Market Report 2020-2026:Chapter 1: Precision Medicine Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Precision Medicine Market ForecastContinued

For More Information with full TOC: https://www.marketinforeports.com/Market-Reports/217480/Precision-Medicine-market

Customization of the Report: Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]: https://www.marketinforeports.com/Market-Reports/Request-Customization/217480/Precision-Medicine-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: s[emailprotected]Website: http://www.marketinforeports.com

Read more from the original source:
Latest Research report on Precision Medicine Market Size predicts favorable growth and forecast 2020 2026| By Top Leading Vendors like Johnson &...

Nov. 23, 2020 08:00 UTC

GHENT, Belgium--(BUSINESS WIRE)-- Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced today the successful first closing of its second fund, Novalis Biotech Acceleration, raising an initial 8 million. With commitments for a similar amount already in place, Novalis anticipates a final closing in early 2021. The majority of investors in Novalis first fund have co-invested in this first closing.

We have already doubled our first fund in this closing and with the commitments in place we are almost fully subscribed to reach our goal of 25 million. With the addition of a couple new investors, we remain on track to fully close the Acceleration Fund in early 2021, said Jan Van den Berghe, co-founder of Novalis.

For the Novalis Acceleration Fund, investments will be split between approximately 10 early stage incubation projects and about 10 acceleration projects, where the investment in each company is larger. Two initial investments have been identified and will close in the near future.

Novalis investment strategy creates a unique ecosystem for healthcare start-ups based on solid foundations of strong scientific and business expertise. The company provides hands-on support for start-ups, allowing an idea to be built into a successful company. In todays disruptive world of new technologies in healthcare like genomics, bioinformatics, diagnostics, personalized medicine, Novalis vision is to bring better healthcare for patients.

Novalis invests early and focuses on capital light ideas, where a relatively small investment can create significant value through the use of software, IP, tools, and other technology that can serve and benefit healthcare. Leveraging extensive academic networks, Novalis translates innovation to viable companies that able to deliver on the founding scientific promise.

Our investment strategy for Fund 1 was very successful. Each company brings a unique perspective to healthcare, many of which are based on our own ideas, said Wim van Criekinge. We will continue this strategy into the Acceleration Fund as well as look at companies where our investment will drive process. There are already a number of companies we have identified for investment as well as plans to incubate a further company based on our internal assessments.

Novalis Fund 1 totalled 4 million that was deployed into eight companies, mostly in the Benelux region, which focused on genomics, bioinformatics and digital health. These include BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO and OHMX.bio. Geographically, the exception was its investment in doc.ai, a digital health company based in the U.S. For Fund 2, Novalis will expand to other areas in Europe and make additional investments in the U.S.

About Novalis

Novalis provides seed funding and ongoing support to biotechnology and life sciences companies. Novalis incubates and advances its own ideas or supports existing innovative life science start-ups. The companys core competence lies in the interaction between bioinformatics, genomics, and digitalization in the life sciences industry. Novalis strongly believes in applying innovative information technology to advance the prevention, diagnosis, or treatment of a disease. For more information, please visit http://www.noval.is.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005574/en/

More here:
Novalis Biotech Announces First Closing of its Second Healthcare Fund - BioSpace

The report aims to offer a clear picture of the current scenario and future growth of the global Cancer Biomarkers Market market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.The report articulates the key opportunities and factors propelling the global Cancer Biomarkers Market market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/1771

Impact of COVID-19 on Cancer Biomarkers Market Industry:

The novel coronavirus pandemic has led to an inevitable recession and impacted the world economy in 2020. Three main factors of the global economy to have been affected are firms and financial markets, supply chains, and production. The report includes a complete, in-depth analysis of the Cancer Biomarkers Market market, featuring the COVID-19 impact, and future outlook of the industry. It divulges the political, economic, social, and technological scenario of the markets.

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Cancer Biomarkers Market market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Cancer Biomarkers Market market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Cancer Biomarkers Market market are Abbott Laboratories, F.Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., Affymetrix Inc., Illumina Inc., Agilent Technologies, Merck & Co. Inc., Hologic Inc., Sino Biological Inc., Becton, Dickinson and Company A comprehensive summary of top foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/1771

KEY MARKET BENEFITS

KEY MARKET SEGMENTS

The global Cancer Biomarkers Market market is segmented on the basis of the following:

Global Cancer Biomarkers Market Market By Product Type:

Global Cancer Biomarkers Market Market By Applications:

Global Cancer Biomarkers Market Market By Regions:

Key Questions Addressed by the Report

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:support@researchdive.comLinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Follow this link:
Penetration: Key instances of the Covid-19 impact on the Cancer Biomarkers Market - The Courier

Sangmi Han discusses how cell counters have become an integral part of Macrogens single-cell RNA sequencing workflow

Macrogen, Inc. is a leading expert in genomic analysis, proactively seeking to improve the fields of genetic and genomic analyses through research and development. To further this mission, Macrogen is working to identify the causal genes for rare diseases with a view to building a big data system that brings together patient genomic and medical data. Using this integrated database, the team aims to help predict disease onset and prognosis, and innovate personalized medicines at an individual level.

Here, we speak with Sangmi Han, Macrogens Head of the Next-Generation Sequencing (NGS) Technical Services Department, about how the LUNA-FX7 Automated Cell Counter from Logos Biosystems has increased the throughput, reliability, and accuracy of her labs single-cell RNA sequencing and precision medicine workflows. Han explains how these state-of-the-art cell counters are helping Macrogen to predict, prevent, and treat diseases on a personal level.

SH: Macrogen is a global leader in precision medicine and biotechnology with the aim of medical innovation for the future by integrating genomic, medical, and life sciences data. We possess the worlds fifth-class genome analysis platform, sequencing and data analysis capacity, and support systematic genome research through precise genome analysis services and personalized medicine that diagnoses, treats, monitors, predicts, and prevents diseases based on the captured genomic information.

SH: I look after whole genome sequencing and metagenome sequencing for microbial identification. When accurate genomic information is obtained from customers and patients, the genes that cause a specific disease can be found based on this sequencing data. Through this genetic analysis, diagnostic kits and panels can be developed with our technology and diseases can be more accurately diagnosed, predicted, prevented, and treated, leading to a much higher quality of patient life.

SH: A current trend in the NGS market is the single-cell library where genes can be analyzed through the unique barcoding of each cell. To construct single-cell sequencing libraries, we count the cells that have been isolated from specific tissues and provided to us by customers. Since we need to perform single-cell RNA sequencing for a certain number of cells in order to enter a sufficient number of barcodes, cell counting is an essential process and must be accurate. In addition, as the demand for single-cell library construction increases, the capacity of cell counting and quality control equipment is becoming ever more important.

To ensure this high accuracy in our cell counts, we use the LUNA-FX7 Automated Cell Counter from Logos Biosystems, the latest and most powerful in the LUNA Family. This instrument provides not only high accuracy but also high throughput, with the LUNA 8-channel slides enabling the counting of eight separate samples at once, fully assisting us in overcoming any potential difficulties we may face during our experiments. We also cross-check these results using manual counting via a microscope. As experimental analysis of single-cell libraries is conducted according to the number of target cells, cell counting is highly important. The better the input number of cells matches the output result, the more reliable the data.

SH: In the NGS market, advanced and precision kits are becoming increasingly popular and being released at a rapid rate. Comprehensive services, from companies like Macrogen, can be provided through the performance of various sequencing analyses, from human to non-human. As a result, we are sure that the use of big data will drastically increase and, due to the vast amount of data available to us, the market size of personal genomics and disease prediction and prevention services will only continue to grow.

Do you use Logos Biosystems products in your lab? Write a review today for your chance to win>>

Read the original:
Editorial Article: Increased NGS throughput for personalized genomics with automated cell counting - SelectScience

Metabolon a biotechnology company based in Durham, North Carolina, has been selected by the NIAID to participate in a study on the coronavirus disease 2019 (COVID-19). The study is a part of the NIAIDs Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) research.

The program is being led by researchers at the Precision Vaccines Program (PVP) at Boston Childrens Hospital. The PVP is a collaboration of academics, government, and industry leaders who are working on advancing the next generation of vaccines for at-risk populations.

It features roughly 400 scientists and administrators around the world through the Precision Vaccines Network (PVN). The PVN employs systems vaccinology, humanin vitromodeling, adjuvant discovery and development through human clinical trials.

The study is focused on researching how a SARs-CoV-2 infection effects the human immune systems response network, focusing mainly on determining the biomarkers of COVID-19 outcome and severity.

The study is supporting the PVPs Clinical Data Collection Center (CDCC), assisting them in their efforts on integrating clinical data like sex, age, and the diseases severity and outcomes with biological data, including metabolomics.

A fundamental aspect to unlocking the genome using multi-omics research, a type of biological analysis, is Metabolomics. This approach aids in population health initiatives and helps in reaching the global goal of personalized medicine.

Metabolon will conduct research on global metabolomics using biological samples of serum from a population of approximately 1000 study participants. The company will collect samples from the participants and examine them across different time points, observing metabolic changes in the immune response to a SARS-CoV-2 infection over time. They will then correlate the data with the severity and outcome of a COVID-19 infection.

"It's an honor to collaborate with NIAID and participating researchers across the U.S. on the IMPACC study to assess and precisely characterize the impact of SARS-CoV-2 on health," Greg Michelotti, PhD, the scientific director of Metabolon, said. "Metabolomics provides a detailed snapshot of the phenotype, enabling deeper understanding of health and disease. The actionable metabolomics insights will help inform development of diagnostics, prognostics, therapeutics and vaccines to address the COVID-19 pandemic."

Follow this link:
Determining the Biomarkers of COVID-19 Outcome and Severity - Contagionlive.com

DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Companion Diagnostic Markets - the Future of Diagnostics, by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

The report includes detailed breakouts for 18 Countries and 4 Regions.

Companion Diagnostic Market - Strategic Situation Analysis

Key Topics Covered:

1. Introduction and Market Definition

2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Personalized Medicine and Companion Diagnostics 2.2.1 Basics 2.2.2 Method 2.2.3 Disease risk assessment 2.2.4 Applications 2.2.5 Diagnosis and intervention 2.2.5.1 Companion Diagnostics 2.2.6 Drug development and usage 2.2.7 Respiratory proteomics 2.2.8 Cancer genomics 2.2.9 Population screening 2.2.10 Challenges 2.2.11 Regulatory oversight 2.2.12 Intellectual property rights 2.2.13 Reimbursement policies2.2.14 Patient privacy and confidentiality 2.3 Chromosomes, Genes and Epigenetics 2.3.1 Chromosomes2.3.2 Genes 2.3.3 Epigenetics 2.4 Cancer Genes 2.4.1 Germline vs Somatic 2.4.2 Changing Clinical Role 2.5 Structure of Industry Plays a Part 2.5.1 New Pharmaceutical Funding Market 2.5.2 Economies of Scale2.5.2.1 Hospital vs. Central Lab 2.5.3 Physician Office Labs 2.5.4 Physicians and POCT

3. Market Trends3.1 Factors Driving Growth3.1.1 Level of Care 3.1.2 Immuno-oncology 3.1.3 Liability3.1.4 Aging Population3.2 Factors Limiting Growth3.2.1 State of knowledge3.2.2 Genetic Blizzard. 3.2.3 Protocol Resistance3.2.4 Regulation and coverage 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing Fuels a Revolution. 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Companion Diagnostics6.1 Global Market Overview by Country6.1.1 Table - Global Market by Country6.1.2 Chart - Global Market by Country 6.2 Global Market by Application - Overview 6.2.1 Table - Global Market by Application 6.2.2 Chart - Global Market by Application - Base/Final Year Comparison 6.2.3 Chart - Global Market by Application - Base Year 6.2.4 Chart - Global Market by Application - Final Year 6.2.5 Chart - Global Market by Application - Share by Year6.3 Global Market Funding Source - Overview 6.3.1 Table - Global Market by Funding Source 6.3.2 Chart - Global Market Funding Source - Base/Final Year Comparison 6.3.3 Chart - Global Market Funding Source - Base Year 6.3.4 Chart - Global Market Funding Source - Final Year6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application 7.1 Oncology 7.1.1 Table Oncology - by Country 7.1.2 Chart - Oncology Growth7.2 Neurology 7.2.1 Table Neurology - by Country 7.2.2 Chart - Neurology Growth 7.3 Cardiology 7.3.1 Table Cardiology - by Country 7.3.2 Chart - Cardiology Growth7.4 Other Application7.4.1 Table Other Application - by Country7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source8.1 Global Market Pharmaceutical 8.1.1 Table Pharmaceutical - by Country8.1.2 Chart - Pharmaceutical Growth 8.2 Global Market Venture 8.2.1 Table Venture - by Country8.2.2 Chart - Venture Growth 8.3 Global Market Clinical 8.3.1 Table Clinical - by Country8.3.2 Chart - Clinical Growth 8.4 Global Market Other Funding 8.4.1 Table Other Funding - by Country 8.4.2 Chart - Other Funding Growth

For more information about this report visit https://www.researchandmarkets.com/r/wci97x

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Outlook on the Companion Diagnostic Global Market to 2025 with COVID-19 Updates - PRNewswire

LAUSANNE, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announced that Riad Sherif M.D., CEO, will present an overview of the company at the following investor conferences:

Date/Time: The company presentation has been made available on demand as of Monday, November 23 at 10AM ET to registered attendees on the conference website. The presentation will be available for playback throughout the duration of the event.

Piper Sandler conferences and events are by invitation only. If you wish to attend, please contact yourPiper Sandlerrepresentative. http://www.pipersandler.com

Date/Time: The company presentation will be made available online as part of a virtual library the week of the event to registered attendees on the conference website.

To access the presentation, please register HERE: https://hcwevents.com/bioconnect/

Dr. Sherif will provide an overview of Oculis portfolio and the significant progress it has made during 2020 with the advancement of its lead candidates OCS-01 and OCS-02.

A key focus of the presentations will be on the development of OCS-01 as a potentially transformative and first topical treatment for Diabetic Macular Edema (DME) and as the first once a day steroid for the treatment of inflammation and pain following ocular surgery. Positive clinical results from Phase 2 trials of OCS-01 in both indications were announced this year in February and May, respectively. The Company is now moving to Phase 3 pivotal trials following a positive End of Phase 2 meeting with FDA in both indications. These trials are expected to start in the first half of 2021.

Dr. Sherif will also discuss progress with OCS-02, a novel and a potentially first-in-class topical anti-TNF alpha antibody. OCS-02 has successfully completed two proof-of-concept (POC) clinical trials in Dry Eye Disease (DED) and Acute Anterior Uveitis and aims to initiate Phase 2b trials in 2021. In DED, Oculis will continue to validate a novel biomarker identified in patients who showed a highly positive response to treatment. If confirmed in the next trial, this finding could accelerate and de-risk the pivotal trials program and potentially lead to a novel, personalized medicine approach to the treatment of DED, with an associated companion diagnostic.

About Oculis

Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients. Oculis novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.

The Companys leading clinical candidates include OCS-01 and OCS-02:

In addition, Oculis formulation discovery focus and capabilities are enabling the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.

Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors. Oculis is headquartered in Lausanne, Switzerland, with research operations in Iceland, and U.S. operations in Boston, MA.

To learn more, visit http://www.oculis.com

Contacts

OculisDr. Riad Sherif, CEOriad.sherif@oculis.comSylvia Cheung, CFOsylvia.cheung@oculis.com Louie-Anne Gauthier, VP, Strategic Marketing and BD&Llouie-anne.gauthier@oculis.com

Media Relations

Citigate Dewe RogersonMark Swallow / Sylvie Berrebi / Marine Perrieroculis@citigatedewerogerson.com+44 (0)20 7638 9571

Originally posted here:
Oculis to Present Progress in its Portfolio of Novel Topical Treatments for Retinal and Front-of-the-Eye Diseases at Upcoming Investor Conferences -...

With their potential to track health continuously outside care facilities, wearables hold a significant potential to improve current precision medicine initiatives.

FREMONT, CA: Wearable devices have come a long way from being just entertaining to bringing in tangible health benefits. Previously, wearables with basic functionality were appreciated by fitness enthusiasts and professional athletes. But today, the capabilities of wearables emerged way beyond counting steps are taken and calories burnt. Next generations of smart wearables expanded their data collection and analytical abilities toward overall health awareness. They start identifying patterns related to the users mood, sleep quality and other vitals. Today, wearables are instead marketed as personal devices for people who is interested in making more informed choices about their health.

This trend of personalized health tracking fell in line with the value-based care paradigm and its stress on precision medicine. The present healthcare industry aspires to leverage wearables as a primary data source to develop highly personal and flexible patient treatment plans, enabling the introduction of timely therapy modifications based on slight alterations in health patterns. Additionally, wearables can also help to promote patients responsibility toward their care routines and encourage informed patient-physician communication. Smart wearable manufacturers and medical-grade software vendors also depend on custom software solutions suitable for clinical use. While researchers and decision-makers can benefit from wearables to support their efforts, it all comes down to two major groups of sensors collecting particular biological signs.

Physiological sensors measure the biological signs with electrical, thermal, acoustic and optical components. It monitors bodily functions like the gut and respiratory activity, vital signs like blood pressure, heart rate, temperature, blood oxygen saturation levels and more. Both consumer-facing and ambulatory-use wearables allow numerous biological tracking options. Some include, smartwatches with the ability to generate ECG, identify falls and abnormal heart rhythms, patch sensors for prenatal contraction monitoring, abdominal patch analyzing gastrointestinal motility and facilitating diagnostics of digestive disorders, and fertility tracker with heart rate, temperature and stress level monitoring capabilities.

Being more aware of their wellness and biological signals, patients can start actively engaging in the dialogue about their therapy. They can consider their possible health outcomes in the long run, and realize that both their opinion and actions matter.

Check This Out:Top Medical Device Consulting Companies

Read the original here:
Wearables Driving the Future of Precision Medicine - Healthcare Tech Outlook

Tissue Sectioning Devices: Introduction

Read Report Overview - https://www.transparencymarketresearch.com/tissue-sectioning-devices-market.html

Key Drivers and Restraints of Global Tissue Sectioning Devices Market

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79999

Growth of personalized therapeutics and diagnostics to boost market

Request for Analysis of COVID-19 Impact on Tissue Sectioning Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79999

Hydrogen Peroxide Tissue Sectioning Devices Segment to Dominate Global Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79999

North America to Dominate Global Tissue Sectioning Devices Market

Pre Book Tissue Sectioning Devices Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79999&ltype=S

Leading Players Operating in Global Tissue Sectioning Devices Market

The global tissue sectioning devices market was highly fragmented in 2019. Key players operating in the global tissue sectioning devices market are:

Browse More Trending Reports by Transparency Market Research:

Over the Counter (OTC) Test Market: https://www.transparencymarketresearch.com/over-the-counter-otc-test-market.html

Alport Syndrome Market: https://www.transparencymarketresearch.com/alport-syndrome-market.html

Female Infertility Drugs Market: https://www.transparencymarketresearch.com/female-infertility-drugs-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read more:
Tissue Sectioning Devices Market: Growth of Personalized Therapeutics and Diagnostics to Boost Market - BioSpace